Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin’s lymphomas. Future Oncol. 2015;11(9):1327–42.

Article  CAS  PubMed  Google Scholar 

Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O’Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verdegaal E, Kooij MKVD, Visser M, Minne CVD, Bruin LD, Meij P, et al. Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. J ImmunoTherapy of Cancer. 2020;8(1): e000166.

Article  Google Scholar 

Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–44.

Article  PubMed  PubMed Central  Google Scholar 

Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842–59.

Article  CAS  PubMed  Google Scholar 

Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.

Article  PubMed  PubMed Central  Google Scholar 

Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, Del Bufalo F. CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies. Front Immunol. 2022;13: 867154.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112–22.

Article  CAS  PubMed  Google Scholar 

Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.

Article  PubMed  PubMed Central  Google Scholar 

Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20(6):1283.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell. 2021;39(2):193-208.e10.

Article  CAS  PubMed  Google Scholar 

MacKay M, Afshinnekoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–44.

Article  CAS  PubMed  Google Scholar 

Alcantara M, Du Rusquec P, Romano E. Current clinical evidence and potential solutions to increase benefit of CAR T-cell therapy for patients with solid tumors. Oncoimmunology. 2020;9(1):1777064.

Article  PubMed  PubMed Central  Google Scholar 

Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022;12(7):1625–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473–88.

Article  CAS  PubMed  Google Scholar 

Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gastric cancer CAR T-cell target antigen ID'd. Cancer Discov. 2021;11(12):2954.

Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res. 2022;10(8):932–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih YP, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615(7953):687–96.

Article  CAS  PubMed  Google Scholar 

Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109(6):2331–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kondo K, Ohigashi I, Takahama Y. Thymus machinery for T-cell selection. Int Immunol. 2019;31(3):119–25.

Article  CAS  PubMed  Google Scholar 

Kass I, Buckle AM, Borg NA. Understanding the structural dynamics of TCR-pMHC complex interactions. Trends Immunol. 2014;35(12):604–12.

Article  CAS  PubMed  Google Scholar 

Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016;37(3):220–30.

Article  CAS  PubMed  Google Scholar 

Sun ZJ, Kim KS, Wagner G, Reinherz EL. Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3 epsilon gamma heterodimer. Cell. 2001;105(7):913–23.

Article  CAS  PubMed  Google Scholar 

Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol. 2011;89(3):396–407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meij P, Jedema I, van der Hoorn MA, Bongaerts R, Cox L, Wafelman AR, et al. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica. 2012;97(8):1205–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pilunov A, Romaniuk DS, Shmelev A, Sheetikov S, Gabashvili AN, Khmelevskaya A, et al. Transgenic HA-1-specific CD8(+) T-lymphocytes selectively target leukemic cells. Cancers (Basel). 2023;15(5):1592.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Balen P, Jedema I, van Loenen MM, de Boer R, van Egmond HM, Hagedoorn RS, et al. HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study. Front Immunol. 2020;11:1804.

Article  PubMed  PubMed Central  Google Scholar 

Dossa RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, Biernacki MA, Foster K, et al. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood. 2018;131(1):108–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535–46.

Article